CURE: Pullback In Healthcare Stocks Presents A Buying Opportunity
The Direxion Daily Healthcare Bull 3X ETF (CURE) has slipped in early 2026 as investors take profits after a strong performance in late 2025. The correction in healthcare stocks comes even as analysts envisage significant gains for CURE's ten largest holdings over the next 12 months. This dynamic may present an opportunity to rotate into CURE from the unlevereged XLV ETF, which tracks the same underlying index.
Which Sector Topped the Leaderboard for January Returns?
The first month of 2026 is already in the books. Which sector walked away with the top spot when it came to total returns?
CURE: Analysts Strike A Cautious Tone Heading Into 2026
The Direxion Daily Healthcare Bull 3X Shares ETF has meaningfully outperformed the S&P 500 so far in 2025, benefiting from a recent shift in sentiment toward health care stocks. While CURE's underlying index is not as cheap as it was a few months ago, it still offers a roughly 19% forward P/E discount relative to the S&P 500. After strong recent returns, analysts project modest single-digit gains over the next 12 months for CURE's largest holdings.
Direxion's 5 Single-Stock ETFs, Including Coinbase and Robinhood
Direxion continues to expand its single-stock ETF offerings for tactical traders. It has introduced five new single stock funds that add exposure to Oracle, Coinbase, Robinhood, and Intel.
These Stocks Could Be Catalysts for CURE
The healthcare sector is catching some flack, and rightfully so. For the three years ending October 15, the S&P Health Care Select Sector Index returned just 22.9%.
CURE: Adding Defensive Exposure Amid Frothy Market Valuations
The Direxion Daily Healthcare Bull 3X Shares ETF tracks an index composed of U.S. healthcare stocks. While the healthcare sector as a whole is essentially flat in 2025, the effect of beta slippage and a high expense ratio has resulted in CURE underperforming unleveraged ETFs. Looking ahead, CURE's underlying index trades at just 17.3x its forward earnings estimates, a wide discount relative to the S&P 500.
Top Performing Leveraged/Inverse ETFs: 08/17/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
CURE: Make an Adventurous Bet on an Undervalued Sector
The healthcare sector, the fifth-largest sector exposure in the S&P 500, was once a reliable destination for investors who wanted dependable performance without taking on significant risk. The group has lived up to its reputation for being less volatile than the broader market.
Top Performing Leveraged/Inverse ETFs: 07/27/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
CURE: A Useful Speculative Tool But Not An Investing Hold
CURE is designed for daily 3x leveraged exposure to the healthcare sector, making it suitable for short-term speculation or hedging, not long-term investment. Daily resets and derivatives costs cause value decay over time, so holding CURE for months or years leads to underperformance versus the underlying index. CURE is effective for tactical trades or hedges on short-term healthcare sector moves, but not for buy-and-hold strategies.
2 Sectors to Trade as Equity Funds See Higher Inflows
Sometimes traders can set up a potential plays when they see where investor money is flowing. This is available with fund inflows, which saw technology and healthcare equities gain a lion's share of February's flows.
5 Leveraged ETFs With Double-Digit Gains Halfway Through Q1
We highlight a bunch of the best-performing leveraged equity ETFs halfway through the first quarter.
